BaseScope RNA ISH is a Powerful Tool for Biomarker Discovery and Validation
"BaseScope™ enabled me to overcome the limitations of antibody-based detection and directly visualize FGFR2 splice isoforms within the tissue context. This has been instrumental in progressing from biomarker discovery to targeted therapy in endometrial cancer."
- Asmerom Sengal, Ph.D., Mater Research Institute, University of Queensland
As part of his groundbreaking research in endometrial cancer, Dr. Asmerom Sengal from Mater Research Institute at University of Queensland, sought to identify prognostic and predictive biomarkers in patients with limited treatment options. One of the major challenges he faced was detecting splice isoforms of FGFR2, which are difficult to differentiate using traditional antibody-based methods due to their high similarity.
Using the BaseScope™ RNA ISH assay, he successfully detected two splice isoforms of FGFR2 (FGFR2b and FGFR2c)—a feat not feasible with standard antibody-based techniques. The BaseScope assay’s high specificity and sensitivity allowed him to visualize RNA expression at single-cell resolution while preserving tissue morphology, leading to the identification of FGFR2b and FGFR2c as novel prognostic and predictive biomarkers.
"In research discovery, the right technique to answer the right question is paramount. BaseScope™ RNA ISH is a powerful tool for biomarker discovery and validation."